An observational study in Stroke, Cardiovascular Diseases and Cardiovascular Risk Factor, sponsored by Norwegian University of Science and Technology. Active, not recruiting at 8 sites in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Norwegian University of Science and Technology · Observational
Annually 13000 Norwegians experience an ischemic stroke. The number of stroke is anticipated to increase with 50% within 2030 due to a growing number of elderly. Many of them will have severe function deficits and reduced quality of life. The investigators have established a cohort consisting of 800 patients with first time ischemic stroke treated at hospitals in Central Norway. The investigators want to study the incidence and prognostic markers for death, recurrent stroke and severe functional deficits during a period of 10 years after the initial ischemic stroke. The investigators want to focus on the impact of physical functioning, the level of physical activity and use of medication for secondary prevention on the incidence of death, recurrent stroke and severe functional deficits. The investigators are especially interested in the importance of fulfilling the treatment targets for blood pressure and cholesterol and the importance of smoking cessation in stroke survivors. Our objective is to improve todays stroke treatment and achieve a more efficient use of the health resources in order to increase survival after stroke maintaining a good physical and psychological function and quality of life.
MIDNOR STROKE is a descriptive prospective longitudinal cohort study, which includes patients with a first event of ischemic stroke admitted to hospitals in Central Norway. The overall objective of this study is to complete a 10-year follow-up of patients with ischemic stroke.
Patient recruitment started 01.09.2015 and ended 01.11.2017. During this time-period, a total of 802 patients were recruited. Patient follow-up at 3 months is completed and follow-up at 12 months will be completed 01.11.18.
All participants met the following inclusion criteria; cerebral infarction according to ICD-10 CM code I63, > 18 years of age, first time stroke, resident in Central-Norway and recruited within a timeframe of 7 days of hospital admission. Patients were excluded if focal neurological symptoms turned out to be not stroke-related or if there were significant physical disabilities prior to stroke (defined as Modified Rankin ≥5)
Eligible stroke patients were recruited during acute stay in hospital. Written informed consent was obtained from all potential stroke patients and from their legal caretakers (mostly a close family member), admitted to the hospital and each subject signed an informed consent form. All participants were examined and treated in line with The Recommended Guidelines for treatment and rehabilitation of stroke, which includes clinical examinations, blood tests, assessment of risk profile and additional relevant examinations.
Stroke patients were recruited and patient data collected by a designated nurse during the initial stay at the hospital. Either a nurse or research assistant in the project performed patient follow-up at 3 and 12 months. Data collected at 3 months included data from a clinical and physical assessment, interview, questionnaires and medical records. Follow-up data at 12 months is collected by phone interview and questionnaires.
The data have been collected at baseline, 3 - and 12 months. Further data collection is planned at 3, 5 and 10 years.
The comprehensive data collection in MIDNOR STROKE at baseline includes data on pre-stroke function (Barthel index, Nottingham ADL, Modified rankin scale), life style risk factors, stroke severity (NIHSS, SSS, TOAST classifications), previous disease, vital signs (i.e. blood pressure, pulse, oxygen saturation), blood values, complications during hospital stay, medication and medical images during hospital stay. Assessment at 3 months included information on physical function, physical activity (HUNT - International physical activity questionnaire), cognitive function (Montreal cognitive assessment), depression (Hospital and anxiety and depression scale), fatigue (Fatigue severity score) and health related quality of life (EQ- 5D- 5L). Data collection at 12 months includes data on physical function, medication, depression, fatigue and health related quality of life.
Additional data will be collected from the Norwegian Stroke Registry, The Norwegian Patient registry, The Norwegian cardiovascular disease registry and The Norwegian Cause of Death registry.
The overall aim for MIDNOR STROKE is to establish a cohort of patients with first- time stroke to study the occurrence and predictors for recurrent stroke, mortality, physical activity, disability and the quality of life during a 10-year period.
MIDNOR STROKE contains six work packages, which address the key areas of interest in the project:
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
This study's enrollment of 800 is above the median of 152 across 1,968 observational studies indexed under Stroke.
Browse Stroke studies →Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated in a hospital in Central Norway for first time ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
Other: no intervention
no intervention
The incidence of recurrent stroke after first ever ischemic stroke
Measured by using data from the Norwegian Stroke Registry and other Norwegian Cardiovascular registries including patient questionnaires
Time frame: 3 months
The incidence of recurrent stroke after first ever ischemic stroke
Measured by using data from the Norwegian Stroke Registry and other Norwegian Cardiovascular registries including patient questionnaires
Time frame: 1 year
The incidence of recurrent stroke after first ever ischemic stroke
Measured by using data from the Norwegian Stroke Registry and other Norwegian Cardiovascular registries including patient questionnaires
Time frame: 3 years
The incidence of recurrent stroke after first ever ischemic stroke
Measured by using data from the Norwegian Stroke Registry and other Norwegian Cardiovascular registries including patient questionnaires
Time frame: 5 years
The incidence of recurrent stroke after first ever ischemic stroke
Measured by using data from the Norwegian Stroke Registry and other Norwegian Cardiovascular registries including patient questionnaires
Time frame: 10 years
Mortality after first ischemic stroke
Measured with data from Norwegian Death Registry
Time frame: 3 months
Mortality after first ischemic stroke
Measured with data from Norwegian Death Registry
Time frame: 1 year
Mortality after first ischemic stroke
Measured with data from Norwegian Death Registry
Time frame: 3 years
Mortality after first ischemic stroke
Measured with data from Norwegian Death Registry
Time frame: 5 years
Mortality after first ischemic stroke
Measured with data from Norwegian Death Registry
Time frame: 10 years
Functional disability after stroke
Modified rankin scale 3 - 5 (the degree of disability, total range 0 - 6, value above 2 represents a worse outcome)
Time frame: 3 months after stroke
Functional disability after stroke
Modified rankin scale 3 - 5 (the degree of disability, total range 0 - 6,value above 2 represents a worse outcome)
Time frame: 1 year after stroke
Functional disability after stroke
Modified rankin scale 3 - 5 (the degree of disability, total range 0 - 6, value above 2 represents a worse outcome)
Time frame: 3 years after stroke
Functional disability after stroke
Modified rankin scale 3 - 5 (the degree of disability, total range 0 - 6, value above 2 represents a worse outcome)
Time frame: 5 years after stroke
Functional disability after stroke
Modified rankin scale 3 - 5 (the degree of disability, total range 0 - 6, value above 2 represents a worse outcome)
Time frame: 10 years after stroke
Health-related quality of life after stroke
EQ-5D-5L (5 Levels from 1-5 in 5 categories where values above 2 represents reduced life quality)
Time frame: 3 months after stroke
Health-related quality of life after stroke
EQ-5D-5L(5 Levels from 1-5 in 5 categories where values above 1 represents reduced life quality)
Time frame: 1 year after stroke
Health-related quality of life after stroke
EQ-5D-5L(5 Levels from 1-5 in 5 categories where values above 1 represents reduced life quality)
Time frame: 3 years after stroke
Health-related quality of life after stroke
EQ-5D-5L (5 Levels from 1-5 in 5 categories where values above 1 represents reduced life quality)
Time frame: 5 years after stroke
Health-related quality of life after stroke
EQ-5D-5L (5 Levels from 1-5 in 5 categories where values above 1 represents reduced life quality)
Time frame: 10 years after stroke
Cost-benefit analysis
Economic analysis that compares the costs of admission to hospital versus outpatient assessment of patients who have had transient ischemic attacks
Time frame: 1, 5 and 10 years
Proportion of patients reaching secondary prevention targets
Blood samples and questionnaire
Time frame: 3 months, 1, 3, 5 and 10 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2015 (actual). Primary completion is estimated for Aug 2026, 135 months after the start.
Of 835 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 135 months is above that.
Counting every sponsor, half of 897 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →